SFI
ALLO icon

Susquehanna Fundamental Investments’s Allogene Therapeutics ALLO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,077
Closed -$17K – 564
2025
Q2 		$17K Sell
15,077
-290,218
-95% -$386K ﹤0.01% 708
2025
Q1 		$446K Sell
305,295
-71,366
-19% -$135K 0.01% 874
2024
Q4 		$802K Buy
+376,661
New +$929K 0.01% 769
2024
Q2 		$976K Buy
418,699
+132,291
+46% +$390K 0.02% 563
2024
Q1 		$1.28M Buy
+286,408
New +$1.2M 0.06% 305
2023
Q4 		– Sell
-161,673
Closed -$513K – 85
2023
Q3 		$513K Sell
161,673
-33,636
-17% -$147K 0.03% 255
2023
Q2 		$971K Hold
195,309
– – 0.04% 337
2023
Q1 		$965K Hold
195,309
– – 0.02% 524
2022
Q4 		$1.23M Buy
+195,309
New +$1.81M 0.02% 605
2021
Q2 		– Sell
-29,657
Closed -$1.05M – 1644
2021
Q1 		$1.05M Buy
+29,657
New +$1M 0.02% 868

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Susquehanna Fundamental Investments's ALLO Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of Allogene Therapeutics (ALLO) in Q3 2025, closing a stake of 15,077 shares — an estimated $17K sold.

Susquehanna Fundamental Investments first reported a position in ALLO in Q1 2021 and held it in 10 quarters. The position peaked at $1.28M in Q1 2024. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Susquehanna Fundamental Investments reported no remaining Allogene Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 15,077 Allogene Therapeutics shares in Q3 2025, an estimated $17K.
  • Susquehanna Fundamental Investments first reported a position in Allogene Therapeutics in Q1 2021 and held it in 10 quarters.
  • Susquehanna Fundamental Investments's Allogene Therapeutics position peaked at $1.28M in Q1 2024.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.